Allovir Stock Quote Today

ALVR
 Stock
  

USD 7.91  0.06  0.76%   

Market Performance
12 of 100
Odds Of Distress
Less than 25
Allovir is selling at 7.91 as of the 30th of September 2022; that is 0.76 percent up since the beginning of the trading day. The stock's lowest day price was 7.76. Allovir has about a 25 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Allovir are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of October 2020 and ending today, the 30th of September 2022. Click here to learn more.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. The company has 65.14 M outstanding shares of which 4.76 M shares are presently shorted by private and institutional investors with about 15.25 trading days to cover. More on Allovir
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Allovir Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Allovir's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Allovir or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Allovir is way too risky over 90 days horizon
Allovir appears to be risky and price may revert if volatility continues
Net Loss for the year was (184.9 M) with profit before overhead, payroll, taxes, and interest of 165 K.
Allovir currently holds about 201.38 M in cash with (133.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.23.
Roughly 35.0% of the company shares are held by company insiders
Acting President and CEOAssaf Katan
Average Analyst Recommendation
Analysts covering Allovir report their recommendations after researching Allovir's financial statements, talking to executives and customers, or listening in on Allovir's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Allovir. The Allovir consensus assessment is calculated by taking the average forecast from all of the analysts covering Allovir.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Allovir's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Allovir (ALVR) is traded on NASDAQ Exchange in USA and employs 110 people. The company currently falls under 'Small-Cap' category with current market capitalization of 481.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allovir's market, we take the total number of its shares issued and multiply it by Allovir's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Allovir conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 65.14 M outstanding shares of which 4.76 M shares are presently shorted by private and institutional investors with about 15.25 trading days to cover. Allovir currently holds about 201.38 M in cash with (133.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.23.
Check Allovir Probability Of Bankruptcy
Ownership
Allovir retains a total of 65.14 Million outstanding shares. Allovir retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Allovir Ownership Details

Allovir Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Allovir jumping above the current price in 90 days from now is about 20.45%. The Allovir probability density function shows the probability of Allovir stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4636. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Allovir will likely underperform. Moreover, the company has an alpha of 1.4147, implying that it can generate a 1.41 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 7.91HorizonTargetOdds Above 7.91
79.49%90 days
 7.91 
20.45%
Based on a normal probability distribution, the odds of Allovir to move above the current price in 90 days from now is about 20.45 (This Allovir probability density function shows the probability of Allovir Stock to fall within a particular range of prices over 90 days) .

Allovir Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Allovir that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Allovir's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Allovir's value.
InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares7.2 M28 M
Alkeon Capital Management LlcCommon Shares2.8 M10.7 M
View Allovir Diagnostics

Allovir Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Allovir market risk premium is the additional return an investor will receive from holding Allovir long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Allovir. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Allovir's alpha and beta are two of the key measurements used to evaluate Allovir's performance over the market, the standard measures of volatility play an important role as well.

Allovir Stock Against Markets

Picking the right benchmark for Allovir stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Allovir stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Allovir is critical whether you are bullish or bearish towards Allovir at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Allovir without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sync Your Broker Now

   

Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

Allovir Corporate Executives

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.

Invested in Allovir?

The danger of trading Allovir is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allovir is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allovir. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allovir is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for analysis

When running Allovir price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Is Allovir's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine Allovir value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.